ALLO
Price
$1.11
Change
-$0.00 (-0.00%)
Updated
Sep 3, 04:59 PM (EDT)
Capitalization
247.4M
56 days until earnings call
SLDB
Price
$5.75
Change
+$0.32 (+5.89%)
Updated
Sep 3 closing price
Capitalization
449.3M
Interact to see
Advertisement

ALLO vs SLDB

Header iconALLO vs SLDB Comparison
Open Charts ALLO vs SLDBBanner chart's image
Allogene Therapeutics
Price$1.11
Change-$0.00 (-0.00%)
Volume$61.9K
Capitalization247.4M
Solid Biosciences
Price$5.75
Change+$0.32 (+5.89%)
Volume$548.63K
Capitalization449.3M
ALLO vs SLDB Comparison Chart in %
Loading...
ALLO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SLDB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ALLO vs. SLDB commentary
Sep 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ALLO is a Hold and SLDB is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 04, 2025
Stock price -- (ALLO: $1.12 vs. SLDB: $5.43)
Brand notoriety: ALLO and SLDB are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ALLO: 71% vs. SLDB: 63%
Market capitalization -- ALLO: $247.4M vs. SLDB: $449.3M
ALLO [@Biotechnology] is valued at $247.4M. SLDB’s [@Biotechnology] market capitalization is $449.3M. The market cap for tickers in the [@Biotechnology] industry ranges from $101.69B to $0. The average market capitalization across the [@Biotechnology] industry is $1.88B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ALLO’s FA Score shows that 0 FA rating(s) are green whileSLDB’s FA Score has 2 green FA rating(s).

  • ALLO’s FA Score: 0 green, 5 red.
  • SLDB’s FA Score: 2 green, 3 red.
According to our system of comparison, SLDB is a better buy in the long-term than ALLO.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ALLO’s TA Score shows that 4 TA indicator(s) are bullish while SLDB’s TA Score has 1 bullish TA indicator(s).

  • ALLO’s TA Score: 4 bullish, 5 bearish.
  • SLDB’s TA Score: 1 bullish, 7 bearish.
According to our system of comparison, ALLO is a better buy in the short-term than SLDB.

Price Growth

ALLO (@Biotechnology) experienced а -3.45% price change this week, while SLDB (@Biotechnology) price change was -4.90% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.32%. For the same industry, the average monthly price growth was +16.10%, and the average quarterly price growth was +32.67%.

Reported Earning Dates

ALLO is expected to report earnings on Oct 30, 2025.

Industries' Descriptions

@Biotechnology (+0.32% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
SLDB($449M) has a higher market cap than ALLO($247M). SLDB YTD gains are higher at: 35.750 vs. ALLO (-47.418). SLDB has higher annual earnings (EBITDA): -152.11M vs. ALLO (-223.22M). ALLO (273M) and SLDB (268M) have equal amount of cash in the bank . SLDB has less debt than ALLO: SLDB (23.1M) vs ALLO (79.2M). ALLO (0) and SLDB (0) have equivalent revenues.
ALLOSLDBALLO / SLDB
Capitalization247M449M55%
EBITDA-223.22M-152.11M147%
Gain YTD-47.41835.750-133%
P/E RatioN/AN/A-
Revenue00-
Total Cash273M268M102%
Total Debt79.2M23.1M343%
FUNDAMENTALS RATINGS
ALLO vs SLDB: Fundamental Ratings
ALLO
SLDB
OUTLOOK RATING
1..100
1050
VALUATION
overvalued / fair valued / undervalued
1..100
97
Overvalued
22
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9798
PRICE GROWTH RATING
1..100
8855
P/E GROWTH RATING
1..100
1003
SEASONALITY SCORE
1..100
6550

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

SLDB's Valuation (22) in the Biotechnology industry is significantly better than the same rating for ALLO (97). This means that SLDB’s stock grew significantly faster than ALLO’s over the last 12 months.

SLDB's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as ALLO (100). This means that SLDB’s stock grew similarly to ALLO’s over the last 12 months.

ALLO's SMR Rating (97) in the Biotechnology industry is in the same range as SLDB (98). This means that ALLO’s stock grew similarly to SLDB’s over the last 12 months.

SLDB's Price Growth Rating (55) in the Biotechnology industry is somewhat better than the same rating for ALLO (88). This means that SLDB’s stock grew somewhat faster than ALLO’s over the last 12 months.

SLDB's P/E Growth Rating (3) in the Biotechnology industry is significantly better than the same rating for ALLO (100). This means that SLDB’s stock grew significantly faster than ALLO’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ALLOSLDB
RSI
ODDS (%)
N/A
Bearish Trend 2 days ago
88%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
89%
Bullish Trend 2 days ago
73%
Momentum
ODDS (%)
Bullish Trend 2 days ago
74%
Bearish Trend 2 days ago
90%
MACD
ODDS (%)
Bullish Trend 2 days ago
69%
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
Bullish Trend 13 days ago
80%
N/A
Declines
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
87%
N/A
Aroon
ODDS (%)
Bullish Trend 2 days ago
76%
Bearish Trend 2 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
ALLO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SLDB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FIQCX29.68N/A
N/A
Fidelity Advisor Asset Manager 85% Z
TCFSCV11.02-0.05
-0.45%
Thrivent Core Small Cap Value
HGASX28.69-0.16
-0.55%
Hennessy Gas Utility Institutional
EVSRX26.59-0.16
-0.60%
Allspring Disciplined US Core R6
SFPAX11.21-0.07
-0.62%
Saratoga Financial Service A

ALLO and

Correlation & Price change

A.I.dvisor indicates that over the last year, ALLO has been loosely correlated with CRSP. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if ALLO jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ALLO
1D Price
Change %
ALLO100%
-0.88%
CRSP - ALLO
54%
Loosely correlated
+1.60%
BEAM - ALLO
52%
Loosely correlated
-0.31%
FATE - ALLO
51%
Loosely correlated
-0.96%
NTLA - ALLO
50%
Loosely correlated
+0.40%
RXRX - ALLO
48%
Loosely correlated
-0.85%
More

SLDB and

Correlation & Price change

A.I.dvisor indicates that over the last year, SLDB has been loosely correlated with BEAM. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if SLDB jumps, then BEAM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SLDB
1D Price
Change %
SLDB100%
-0.91%
BEAM - SLDB
49%
Loosely correlated
-0.31%
EDIT - SLDB
47%
Loosely correlated
-3.89%
ALLO - SLDB
44%
Loosely correlated
-0.88%
DSGN - SLDB
44%
Loosely correlated
+3.62%
SYRE - SLDB
43%
Loosely correlated
+0.85%
More